Document is current
Any future updates will be listed below
-
Authors
Filsinger, Gabriel T. https://orcid.org/0000-0001-6695-2934
Wannier, Timothy M. https://orcid.org/0000-0002-4165-4751
Pedersen, Felix B. https://orcid.org/0000-0003-4232-8613
Lutz, Isaac D.
Zhang, Julie
Stork, Devon A.
Debnath, Anik
Gozzi, Kevin
Kuchwara, Helene
Volf, Verena
Wang, Stan https://orcid.org/0000-0003-2260-2523
Rios, Xavier
Gregg, Christopher J.
Lajoie, Marc J. https://orcid.org/0000-0002-0477-5511
Shipman, Seth L.
Aach, John
Laub, Michael T. https://orcid.org/0000-0002-8288-7607
Church, George M. https://orcid.org/0000-0003-3535-2076
-
Funding
Funding for this research was provided by:
National Science Foundation (DGE1745303, DGE1745302)
U.S. Department of Health & Human Services | National Institutes of Health (R01GM082899)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1U01GM110714-01)
DOE | Advanced Research Projects Agency - Energy (DE-FG02-02ER63445)
- License Information
-
More Information
Article History
Received: 14 April 2020
Revised: 2 November 2020
Accepted: 13 November 2020
First Online: 18 January 2021
Competing interests
: G.M.C. is a founder of 64-x, enEvolv and GRO Biosciences. G.T.F., T.M.W. and G.M.C. are named inventors on a patent application related to the technologies described in this Article. Other potentially relevant financial interests are listed at .
